Hip fractures in users of first- vs. second-generation bisphosphonates
- M. MamdaniAffiliated withKeenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael’s HospitalInstitute for Clinical Evaluative SciencesUniversity of Toronto Faculty of PharmacyUniversity of Toronto Faculty of MedicineDepartment of Health Policy, Management and Evaluation, University of Toronto
- , A. KoppAffiliated withInstitute for Clinical Evaluative Sciences
- , G. HawkerAffiliated withInstitute for Clinical Evaluative SciencesUniversity of Toronto Faculty of MedicineWomen’s College HospitalDepartment of Health Policy, Management and Evaluation, University of Toronto Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
This study compared population hip fracture rates for women with a prior fragility fracture who were treated with first-generation versus second-generation bisphosphonate therapies. The observational study found that, relative to women treated with etidronate, a first-generation bisphosphonate, women treated with the second-generation therapies ‘alendronate’ or ‘risedronate’ were equally likely to be admitted to hospital for hip fracture. Our findings must be confirmed in large randomized head-to-head controlled trials.
Few studies have examined hip fracture outcomes among users of first- versus second-generation bisphosphonates. We compared hip fracture rates among elderly women with a history of fracture dispensed first- and second-generation bisphosphonates, hypothesizing that hip fracture rates would be higher among users of first- versus second-generation bisphosphonates after adjusting for confounders.
Administrative data from Ontario, Canada from 01 April 1998 to 31 March 2002 was used to identify population-based bisphosphonate-naïve cohorts of subjects age 66 years and older initiated on first- (etidronate plus calcium; n = 19,127) or second-generation (alendronate or risedronate; n = 1,460) bisphosphonates. Multivariate Cox proportional hazard models were used for analysis.
During over 23,000 person-years of follow-up, we observed 293 hospital admissions for first hip fracture. The unadjusted event rates yielded approximately 12.5 hospital admissions for hip fracture per 1,000 person-years of follow-up in each study group. Relative to the etidronate plus calcium group, females in the alendronate or risedronate group were equally likely to be admitted for hip fracture (adjusted rate ratio [aRR] = 1.0; 95% CI 0.6–1.6).
The findings of this study suggest similar rates of hip fracture between the first- and second-generation bisphosphonates when used continuously among elderly females with a prior history of fracture.
KeywordsBisphosphonates Hip fractures Observational cohort study Postmenopausal osteoporosis
- Hip fractures in users of first- vs. second-generation bisphosphonates
Volume 18, Issue 12 , pp 1595-1600
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Hip fractures
- Observational cohort study
- Postmenopausal osteoporosis
- Industry Sectors
- Author Affiliations
- 1. Keenan Research Centre, Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Canada
- 2. Institute for Clinical Evaluative Sciences, Toronto, ON, Canada
- 3. University of Toronto Faculty of Pharmacy, Toronto, ON, Canada
- 4. University of Toronto Faculty of Medicine, Toronto, ON, Canada
- 6. Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada
- 5. Women’s College Hospital, 76 Grenville Street, Room 814, Toronto, ON, M5S 1B2, Canada